[1] Wang J, Wu W, Yan X, et al. HBeAg negativity is associated with more advanced liver fibrosis in patients with chronic hepatitis B:apropensity score-matching analysis. J Clin Gastroenterol,2019,11(27):1091-1097. [2] Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis:ready for prime time. Gastroenterol Clin North Am,2011.40(3):507-521. [3] Shiha G, Ibrahim A, Helmy A, et a1. Asian-pacific association for the study of the liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:A 2016 update.Hepatol Int,2017,11(1):1-30. [4] ShneiderBL, Magee JC, Karpen SJ, et al. Total serum bilirubin within 3 months of hepatoportoenterostomy predicts short-term outcomes in biliary atresia. 2016,170(6):211-217. [5] Qi X, Liu X, Zhang Y, et al. Serum liver fibrosis markers in the prognosis of liver cirrhosis:A prospective observational study. Med Sci Monit, 2016,22:2702-2703. [6] Zhu M, Han M, Xiao X, et al. Dynamic differences of red cell distribution width levels contribute to the differential diagnosis of hepatitis B virus-related chronic liver diseases:A case-control study.Int J Med Sci,2019,16(5):720-728. [7] Elaghori A, Salem P, Azzam E, et al. Ghrelin level in patients with liver C cirrhosis. Acta Endocrinol(Buchar),2019,5(1):62-68. [8] Ng KJ, Tseng CW, Chang TT, et al. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.Clin Interv Aging, 2016,11:1035-1041. [9] Kothari HG, Gupta SJ, Gaikwad NR, et al. Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India.Turk J Gastroenterol, 2019,30(12):1036-1043. [10] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):S9-S32. [11] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案.中华内科杂志2001,40(1):62-68. [12] Nayagam S,Thursz M, Sicruri E, et al.Requirements for global elimination of hepatitis B:a modelling study.Lancet Infect Dis,2016,16(12):1399-1408. [13] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol,2019,70(1):151-171. [14] Li J, Gordon SC, Rupp LB, et al. Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.J Gastroenterol Hepatol,2017,32(6):1250-1257. [15] Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio(GPR)predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.Gut,2016,65:1369-1376. [16] Li Q, Song J,Huang Y,et al. The gamma-glutamyl-transpeptidase to platelet ratio?does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B:a retrospective cohort study in China.Medicine,2016,95(16):e3372. [17] Wang RQ,Zhang QS,Zhao SX,et al. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients.J Int Med Res,2016,44(6):1302-1313. [18] Huang R,Wang G,Tian C,et al. Gamma-glutamyl-transpeptidase to platelet ratiois not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China.Sci Rep,2017,21(7):8543. [19] Ren T,Wang H,Wu R,et al. Gamma-glutamyl transpeptidase-to-platelet ratio predicts significant liver fibrosis of chronic hepatitis B patients in China.Gastroenterol Res Pract,2017,2017:7089702. [20] Mcmahon BJ. Natural history of chronic hepatitis B.Clin Liver Dis,2010,14:381-396. |